About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04212286

Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC

HCC is a serious threat to the health of people. Accurate diagnosis of early HCC by imaging allows patients to obtain proper treatment. However, for lesions with diameters ≤2 cm, the tumor blood suppl...

Lead sponsor: Tianjin Third Central Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Tianjin Third Central Hospital

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients are at high risk of HCC.
•2. The ages of patients are between 18 and 80.
•3. Patients are with solid liver lesion(s) ≤ 2 cm detected by imaging scan (US/CT/MRI).
•4. The number of lesions is less than or equal to 3.
•5. Patient is able and willing to receive CEUS and EOB-MRI examinations within 30 days.
•6. Patient signs the informed consent.

Exclusion Criteria

•1. Patient is with lesions confirmed by pathology or follow-up, or hemangiomas.
•2. Patient is with lesions already undergoing local treatment, including thermal ablation or TACE.
•3. Patient is with severe cardiopulmonary insufficiency.
•4. Patient is a pregnant or breastfeeding women.
•5. Patient is considered to be unsuitable to participate in the study.

Related studies

Artificial Intelligence for Highly Myopic Cataract

NCT06616506 · Cataract, High Myopia, and more

RECRUITINGPhase 1

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

NCT05003895 · Hepatocellular Carcinoma, Hepatocellular Cancer, and more

RECRUITINGPhase 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813 · Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer

Developing Viability Index for Machine Perfused Livers

NCT03694691 · Liver Cirrhoses

RECRUITINGPhase 2

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

NCT04912765 · Hepatocellular Carcinoma, Hepatocellular Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 7, 2022Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment115

Start dateOct 2019

Last updatedMar 7, 2022

Condition

Hepatocellular Cancer Liver Cirrhoses Diagnoses Disease

Locations shown

Tianjin Third Central Hospital

Tianjin, Tianjin Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions